REG - Solvonis Therapeutic - Granted U.S. Patent from PTSD Discovery Programme

Solvonis TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe7147Ya&default-theme=true

RNS Number : 7147Y  Solvonis Therapeutics PLC  31 March 2026

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

31 March 2026

 

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

Granted U.S. Patent from PTSD Discovery Programme

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system ("CNS") disorders, announces it has been granted a U.S. patent by the
United States Patent and Trademark Office ("USPTO") covering a monoamine
modulator compound series arising from its proprietary post-traumatic stress
disorder ("PTSD") discovery programme.

The patent, U.S. Patent No. 12,590,077, covers a monoamine modulator compound
series designed to modulate serotonin, dopamine and noradrenaline transporter
systems (SERT, DAT and NET).

PTSD is a large and underserved market affecting more than 20 million people
across the UK, U.S. and major European markets, with limited approved
pharmacological treatment options. Recent strategic activity in the sector,
including Otsuka Pharmaceutical Co., Ltd.'s ("Otsuka") agreement to acquire
Transcend Therapeutics for total potential consideration of US$1.225 billion,
highlights growing strategic and commercial interest in next-generation PTSD
treatments.

As a composition-of-matter patent, it protects the underlying compounds
themselves rather than only how they are used or manufactured. This is
generally regarded as the strongest and most commercially valuable form of
patent protection in drug development.

The granted patent builds on the Company's previously announced USPTO patent
allowance in January 2026 in relation to compounds arising from its PTSD
discovery programme. Since that milestone, Solvonis has also selected SVN-114
as the lead candidate from the programme.

Importantly, this patent is part of a broader protected chemistry estate being
built around the Company's PTSD discovery programme, providing additional
optionality for future optimisation, lifecycle management and potential
follow-on development.

Anthony Tennyson, CEO of Solvonis Therapeutics plc, commented: "This patent
strengthens the long-term value of our PTSD programme in an area of clear
unmet need and rising strategic and commercial interest, highlighted by
Otsuka's agreement to acquire Transcend Therapeutics for total potential
consideration of US$1.225 billion. Strong intellectual property is central to
value creation in biotech, and securing composition-of-matter protection at
the level of the underlying compounds materially strengthens our position.
Importantly, it supports a broader chemistry platform beyond a single asset,
giving us greater flexibility as we advance SVN-114 and continue to expand our
CNS pipeline."

Professor David Nutt, Chief Scientific Officer of Solvonis Therapeutics plc,
added: "This patent reflects one of the chemically distinct series arising
from our monoamine modulation research. Exploring multiple series is a
deliberate strategy because it provides alternative compounds and
differentiated profiles to support future optimisation and development."

 

 

Enquiries:

 

 Solvonis Therapeutics plc                                       Via Walbrook
 Anthony Tennyson, CEO & Executive Director
 Singer Capital Markets (Broker)                                 +44 (0) 20 7496 3000
 Phil Davies

 Walbrook PR (PR/IR advisers)  Tel: +44 (0)20 7933 8780 or solvonistherapeutics@walbrookpr.com
                               (mailto:solvonistherapeutics@walbrookpr.com)
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001
 Lianne Applegarth                                               Mob: +44 (0)7584 391 303
 Rachel Broad                                                    Mob: +44 (0)7747 515 393

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing small-molecule therapeutics for high-burden central nervous system
(CNS) disorders. Headquartered in London and listed on the main market of the
London Stock Exchange, Solvonis is advancing a differentiated pipeline of
repurposed and discovery-stage compounds across addiction and psychiatry.

 

The Company's lead programmes target Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional development and
discovery work supporting expansion into further addiction and psychiatric
indications, including stimulant use disorder and depressive disorders.

 

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK,
while SVN-002 is preparing for a Phase 2b trial in the United States targeting
moderate-to-severe AUD. The Company's PTSD discovery programme has identified
SVN-114 as a lead compound, emerging from a proprietary compound series
designed to modulate key brain signalling systems associated with emotional
processing and social behaviour.

 

In parallel, Solvonis is advancing proprietary CNS discovery programmes
supported by a dedicated compound library to identify new small-molecule
modulators of key neurotransmitter systems. This platform enables efficient
early-stage innovation and supports the Company's integrated approach to
developing therapies across addiction and psychiatry.

 

With a capital-efficient development model and a focus on partnering
opportunities, Solvonis aims to deliver sustained value through innovation in
CNS therapeutics.

 

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEDEDENKEAA



            Copyright 2019 Regulatory News Service, all rights reserved